Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE ·
6ix hasn’t read this filing yet.
Nanjing Pharmaceutical Group Company Limited on 6ix
Earlier from Nanjing Pharmaceutical
- Announcement on Resolutions of the 2025 Annual General Meeting
- Report for Q1 2026
- Announcement on Issuance Result of Phase VI Ultra-Short-Term Financing Bonds of 2026
- Announcement on Progress in Government’s Expropriation of Certain Real Estate and Land of the Company’s Tier-II Subsidiary
- Announcement on Election of Employee Representative Directors for the 10th Board of Directors
Later from Nanjing Pharmaceutical
- Announcement on Termination of Outward Investment
- Announcement on Resolutions of the Extraordinary Meeting of the 10th Board of Directors
- Announcement on Outline of the Performance Briefing for 2025 and Q1 2026
- Announcement on Issuance Result of Phase I Medium-term Notes of 2026
- Announcement on Issuance Result of Phase VII Ultra-Short-Term Financing Bonds of 2026
Follow Nanjing Pharmaceutical into a list and get an email when it puts out news.
Follow Nanjing Pharmaceutical